Following the approval of Lecanemab (brand name: Leqembi) by Eisai/Biogen, the second new Alzheimer's disease drug approved in China from Eli Lilly and Co has been launched. On December 18, Eli Lilly and Co announced that the global second Alzheimer's disease (AD) new drug Donanemab injection (brand name: Kintor) received approval from the National Medical Products Administration of China for the treatment of adults with mild cognitive impairment and mild dementia due to Alzheimer's disease. Regarding whether the price of the second global Alzheimer's disease new drug will decrease, a medical expert told reporters that this usually depends on various factors, including market demand, drug efficacy, production costs, and market competition. As more similar drugs are developed and marketed, market competition may intensify, which could lead to price reductions. However, this also needs to consider the high costs of drug development and companies' profit requirements. (KE Holdings)
礼来阿尔茨海默病新药上市：一年药费超3万美元 辉瑞罗氏在布局
Eli Lilly and Co has launched a new drug for Alzheimer's disease: annual medication costs exceed 0.03 million dollars. Pfizer and Roche are making arrangements.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.